2017
DOI: 10.3389/fphar.2017.00855
|View full text |Cite
|
Sign up to set email alerts
|

Drugs and Targets in Fibrosis

Abstract: Fibrosis contributes to the development of many diseases and many target molecules are involved in fibrosis. Currently, the majority of fibrosis treatment strategies are limited to specific diseases or organs. However, accumulating evidence demonstrates great similarities among fibroproliferative diseases, and more and more drugs are proved to be effective anti-fibrotic therapies across different diseases and organs. Here we comprehensively review the current knowledge on the pathological mechanisms of fibrosi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
99
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
5
3
1

Relationship

1
8

Authors

Journals

citations
Cited by 89 publications
(99 citation statements)
references
References 204 publications
0
99
0
Order By: Relevance
“…Pharmaceutical agents can be designed to prevent the progression of fibrosis and reverse steatohepatitis (8). Excessive ECM production by activated HSCs, portal myofibroblasts (MFs), and activated sinusoidal endothelial cells can be targeted in the development of antifibrotic agents (2).…”
mentioning
confidence: 99%
“…Pharmaceutical agents can be designed to prevent the progression of fibrosis and reverse steatohepatitis (8). Excessive ECM production by activated HSCs, portal myofibroblasts (MFs), and activated sinusoidal endothelial cells can be targeted in the development of antifibrotic agents (2).…”
mentioning
confidence: 99%
“…Hence. the activity of paquinimod, a novel anti-inflammatory compound initially developed against Systemic Lupus Erythematosus (SLE) that targets S100A9, one subunit of the S100A8/A9 complex, in liver, lung, heart and skin (37), was tested in vitro . The percentage of dead cells (propidium iodide positive cells) using flow cytometry analysis (FACS) was assessed on treatment of WT BMDMs with various drug concentrations of paquinimod.…”
Section: Resultsmentioning
confidence: 99%
“…Therefore, one strategy to stimulate regeneration after proximal amputation may be the exogenous administration of degradative enzymes, which can decrease ECM density and stiffness (Qu et al, 2018) and trigger cell proliferation and migration (Qu et al, 2017;Qu et al, 2015). Modulating early scar formation by targeting fibrotic signaling pathways (Li et al, 2017) may also give stem/progenitor cells an opportunity to expand and differentiate. Finally, spatiotemporal delivery of morphogenic signaling molecules by genetically modified cells and/or biomaterials may help direct and sustain the regenerative process Taghiyar et al, 2017;Qu et al, 2017).…”
Section: Discussionmentioning
confidence: 99%